[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Novo Nordisk A\u002FS\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":503},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,75,0,25,[9,44,61,84,107,127,150,159,168,188,208,230,252,272,292,314,331,350,368,389,412,430,449,466,489],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100053553","phase-3-amaze-3-a-research-study-investigating-how-well-the-medicine-nnc0487-0111-helps-people-with-excess-body-weight-and-obstructive-sleep-apnoea-not-treated-with-positive-airway-pressure-lose-weight-and-improve-sleep-apnoea-100053553",false,"NCT07571005","AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea","Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure (AMAZE 3)","AMAZE 3","Key Inclusion Criteria:\n\n* Male or female (sex at birth)\n* Age 18 years or above at the time of signing informed consent\n* Previously diagnosed moderate-to-severe OSA with an AHI ≥ 15, as diagnosed with polysomnography (PSG), home sleep apnoea test (HSAT), or other method that meets local guidelines prior to screening\n\nKey Exclusion Criteria:\n\n* Glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol\u002Fmol) as measured by the central laboratory at screening\n* History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records\n* Any planned or previous surgery within 90 days prior to screening for sleep apnoea, including septoplasty, turbinoplasty, or other ear, nose, and throat surgeries, including tonsillectomy and adenoidectomy\n* Significant craniofacial abnormalities that may affect breathing at baseline, for example Treacher Collins syndrome and Pierre Robin Sequence\n* Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonist (RA), dual GLP-1\u002Fgastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening","ALL","18 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with excess body weight and obstructive sleep apnoea not treated with positive airway pressure lose weight and improve sleep apnoea. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it) and which treatment participants get is decided by chance.",[28,29,30],"Obesity","Overweight","Obstructive Sleep Apnoea","RECRUITING","2026-07-09",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":35},"2026-05-05",{"date":39,"type":22},"2028-10-04",{"name":41,"class":42},"Novo Nordisk A\u002FS","INDUSTRY",80,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":55,"startDateStruct":56,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},"100054210","phase-3-amaze-4-a-research-study-investigating-how-well-the-medicine-nnc0487-0111-helps-people-with-excess-body-weight-and-obstructive-sleep-apnoea-treated-with-positive-airway-pressure-lose-weight-and-improve-sleep-apnoea-100054210","NCT07571109","AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea","Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Obstructive Sleep Apnoea Treated With Positive Airway Pressure (AMAZE 4)","AMAZE 4",{"count":21,"type":22},[25],"This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it) and which treatment participants get is decided by chance.",[28,29,30],{"date":34,"type":35},{"date":37,"type":35},{"date":58,"type":22},"2028-08-21",{"name":41,"class":42},92,{"id":62,"slug":63,"hasResults":12,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},"100645368","management-concepts-of-metabolic-dysfunction-associated-steatotic-liver-disease-masld-among-chinese-physicians-100645368","NCT07682363","Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese Physicians","Attitudes, Perceptions, Clinical Practice, and Barriers in Diagnosis and Management of Patients With Metabolic Dysfunction-associated Steatotic Liver Disease: a Cross-sectional Survey on Physicians in China","Inclusion Criteria:\n\n* Has provided informed consent.\n* Registered clinical practice location in provincial capital or municipality.\n* Physician with a license for clinical practice.\n* Employed in the Department of Endocrinology, Hepatology, Infection or Gastroenterology.\n* Hospital level: Grade IIIA hospital.\n* Hold a professional title of associate chief physician or above, or senior attending physician (as an attending physician for more than or equal to (≥) 3 years).\n* Conducts outpatient clinics for at least 1 half-days per week.\n* The patient load of MASLD\u002FMASH per month in the department should be:\n* a. Endocrinology ≥20 patients per month\n* b. Hepatology\u002FGastroenterology\u002F Infectious ≥30 patients per month\n\nExclusion Criteria:\n\n-Participants will be excluded if they have unwillingness precluding adequate cooperation, fail to complete the questionnaire, or submit questionnaires verified as invalid.",true,{"count":70,"type":22},470,"OBSERVATIONAL","This study is a cross-sectional survey-based study. The main goal of this study is to investigate the attitudes, perceptions, and clinical practice in assessing liver fibrosis following a metabolic dysfunction-associated steatotic liver disease (MASLD) diagnosis, and the management of MASLD patients among Chinese physicians in the departments of endocrinology \u002F hepatology \u002F infection \u002F gastroenterology in Grade IIIA hospitals in provincial capitals or municipalities.",[74],"Liver Disease","2026-06-26",{"date":77,"type":35},"2026-07-02",{"date":79,"type":35},"2026-06-03",{"date":81,"type":22},"2027-02-23",{"name":41,"class":42},1,{"id":85,"slug":86,"hasResults":12,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":94,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100624924","phase-2-a-research-study-comparing-how-well-different-doses-of-the-medicine-nnc0662-0419-lower-blood-sugar-in-people-with-type-2-diabetes-100624924","NCT07415954","A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes","Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study","Inclusion criteria\n\n* Male or female (sex at birth).\n* Age 18-75 years (both inclusive) at the time of signing the informed consent.\n* Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole \\[mmol\u002Fmol\\]) (both inclusive) as assessed by central laboratory at screening.\n* Willingness to obtain a high weight loss (greater than \\[\\>\\] 25% of weight at baseline).\n\nExclusion criteria\n\n* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.\n* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.\n* Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.","75 Years",{"count":93,"type":22},270,[95],"PHASE2","This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.",[98],"Diabetes Mellitus, Type 2",{"date":100,"type":35},"2026-06-30",{"date":102,"type":35},"2026-04-17",{"date":104,"type":22},"2027-10-01",{"name":41,"class":42},63,{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},"100578122","general-use-results-surveillance-with-awiqli-in-patients-with-diabetes-mellitus-100578122","NCT06807190","General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus","A Multi-centre, Prospective, Open Label, Non-interventional, Single-armed, 52 Weeks Post-marketing Study to Investigate Safety and Clinical Parameters of Awiqli Once Weekly in Patients With Diabetes Mellitus Under Real-world Clinical Practice Setting in Japan","Inclusion Criteria:\n\n* Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).\n* The decision to initiate treatment with commercially available Awiqli has been made by the patient\u002FLegally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.\n* Male or female with no age limitation.\n* Diagnosis of diabetes mellitus. There is no limitation for type of diabetes mellitus and prior treatment for diabetes mellitus.\n\nExclusion Criteria:\n\n* Previous participation in this study. Participation is defined as having given informed consent in this study.\n* Treatment with any investigational drug within 30 days prior to enrolment into the study.\n* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.\n* Contraindication described in Japanese package insert.\n* Participants showing hypoglycaemic symptoms.\n* Participants with a history of hypersensitivity to any ingredients of this drug.",{"count":115,"type":22},630,"The purpose of the study is to investigate the safety and effectiveness of Awiqli in participants with diabetes mellitus under real world clinical practice in Japan. Participants will get Awiqli as prescribed by the study doctor. The study will last for about 1 year.",[118],"Diabetes Mellitus, Type 1",{"date":120,"type":35},"2026-06-29",{"date":122,"type":35},"2025-04-15",{"date":124,"type":22},"2028-01-31",{"name":41,"class":42},112,{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":68,"sex":18,"minAge":19,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":83},"100641149","phase-1-a-study-understanding-how-much-cdr132l-enters-the-bloodstream-after-injection-under-the-skin-compared-to-injection-into-a-vein-in-healthy-participants-100641149","NCT07656454","A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy Participants","A Bioavailability Study Comparing the Pharmacokinetics of CDR132L Following Subcutaneous and Intravenous Administration in Healthy Participants","Inclusion Criteria:\n\n* Male or female (sex at birth).\n* Age 18-55 years (both inclusive) at the time of signing the informed consent.\n* Body mass index 18.5-29.9 kilograms per square metre (kg\u002Fm\\^2) (both inclusive) and body weight less than or equal to (≤) 120 kilograms (kg) at screening (visit 1).\n* Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit (visit 1), as judged by the investigator.\n\nExclusion Criteria:\n\n* Any laboratory safety parameters at screening (visit 1) outside the below laboratory ranges, see laboratory manual for specific values.\n\n  * Alanine aminotransferase (ALT) greater than (\\>) upper limit of normal (ULN) +10 percentage (%)\n  * Aspartate aminotransferase (AST) \\>ULN +20%\n  * Bilirubin \\>ULN +20%\n  * Creatinine \\>ULN +10%\n  * Estimated glomerular filtration rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\]) less than (\\\u003C) 90 milliliters per minute\u002F1.73square meter (mL\u002Fmin\u002F1.73m\\^2)\n  * Urine albumin-to-creatinine ratio (UACR) greater than or equal to (≥) 30 milligrams per gram (mg\u002Fg)\n* Second or third degree atrioventricular-block, prolongation of the QRS complex over 120 milliseconds (ms), or of the QT interval corrected using Fridericia's formula (QTcF) interval over 450 ms, or any other clinically significant abnormal electrocardiogram results as judged by the investigator at screening (visit 1).\n* Supine blood pressure at screening (visit 1) outside the range of 90-139 millimeters of mercury (mmHg) for systolic or 50-89 mmHg for diastolic.\n* Heart rate outside the range of 50-89 beats\u002Fminute at screening (visit 1).\n* Presence or history (as declared by the participant or reported in the medical records) of cardiovascular disease including stable and unstable angina pectoris, myocardial infarction, transient ischaemia, stroke, heart failure, cardiac decompensation, clinically significant arrhythmia and clinically significant conduction disorders.\n* Known history of severe symptomatic untreated anaemia in the 90 days prior to screening (visit 1) (e.g., haemoglobin \\\u003C90 grams per litre (g\u002FL))\n* Presence or history (as declared by the participant or reported in the medical records) of acute or chronic kidney disease or injury.\n* Presence of thrombocytopenia, defined as thrombocyte count \\\u003C150 x 10\\^9 cells\u002FL at screening (visit 1), or history (as declared by the participant or reported in the medical records) of bleeding disorder.\n* Presence or history (as declared by the participant or reported in the medical records) of conditions associated with disruption of blood-brain barrier (e.g. multiple sclerosis).","55 Years",{"count":136,"type":22},32,[138],"PHASE1","This study is being done to understand how much of the medicine (CDR132L) enters the bloodstream after injection under the skin compared to injection into a vein in healthy people. This will help us find the best way to give the medicine to people living with heart failure. The study will assess what the body does to the medicine, and how safe it is.",[141,142],"Healthy Volunteers","Heart Failure","2026-06-25",{"date":100,"type":35},{"date":146,"type":35},"2026-06-17",{"date":148,"type":22},"2026-12-31",{"name":41,"class":42},{"id":151,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":23,"phases":153,"briefSummary":26,"conditions":154,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":157,"leadSponsor":158,"locationsCount":43},"100636847",{"count":21,"type":22},[25],[28,29,30],{"date":75,"type":35},{"date":37,"type":35},{"date":39,"type":22},{"name":41,"class":42},{"id":160,"slug":4,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":53,"conditions":163,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":166,"leadSponsor":167,"locationsCount":60},"100636855",{"count":21,"type":22},[25],[28,29,30],{"date":120,"type":35},{"date":37,"type":35},{"date":58,"type":22},{"name":41,"class":42},{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":187},"100636539","phase-3-a-research-study-to-look-at-how-well-nnc0487-0111-works-compared-to-placebo-in-people-with-heart-failure-and-obesity-100636539","NCT07567001","A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity","Efficacy and Safety of NNC0487-0111 Compared to Placebo on Morbidity and Mortality in People With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity","HF-POLARIS","Inclusion Criteria:\n\n* Body Mass Index (BMI) greater than or equal to (\\>=) 30 kilograms per square metre (kg\u002Fm\\^2) at screening.\n* Diagnosis of HF with New York Heart Association (NYHA) class II-IV and in stable condition at screening, at the discretion of the investigator.\n\nFor participants with Type 2 Diabetes (T2D) at screening:\n\n\\- Diagnosed with T2D \\>= 30 days before screening.\n\nExclusion Criteria:\n\n* MI, stroke, unstable angina pectoris or worsening HF leading to either hospitalization or intravenous loop diuretics within 30 days prior to the day of screening and until randomization.\n* HF due to infiltrative cardiomyopathy (e.g., sarcoid, amyloid), arrhythmogenic right ventricular cardiomyopathy, Takutsubo cardiomyopathy, Chagas cardiomyopathy, genetic hypertrophic cardiomyopathy or obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, or uncorrected primary valve disease of moderate or severe degree.\n* Severe pulmonary disease including primary pulmonary hypertension, chronic pulmonary embolism, or severe chronic obstructive pulmonary disease (COPD) defined as:\n* requiring home oxygen; or - ongoing oral corticosteroid therapy; or - hospital for COPD Exacerbation within 12 months prior to screening.\n* Any other condition judged by the investigator to be the cause of HF symptoms (e.g., anaemia, hypothyroidism).\n\nGlycaemia-related:\n\n* History of type 1 diabetes.\n* Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or who, at the time of screening, are expected to require treatment within 180 days after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomization. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.\n* Glycated haemoglobin (HbA1c) greater than (\\>) 10 percent (%) (86 \\[millimoles per mole\\] mmol\u002Fmol) as measured by local or central laboratory at screening.",{"count":177,"type":22},5610,[25],"This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have HFpEF or HFmrEF and excess body weight. Participants will get NNC0487-0111 or placebo by injection once a week. Which treatment participants get is decided by chance. NNC0487-0111 is a new medicine that doctors cannot prescribe yet, but it has been tested in people before.",[28,142],{"date":100,"type":35},{"date":183,"type":35},"2026-05-11",{"date":185,"type":22},"2029-08-15",{"name":41,"class":42},838,{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":23,"phases":198,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":201,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":207},"100598800","phase-3-a-research-study-to-see-how-a-weekly-insulin-insulin-icodec-helps-in-reducing-the-blood-sugar-compared-to-daily-insulin-glargine-both-in-combination-with-insulin-aspart-in-adults-with-type-1-diabetes-100598800","NCT07076199","A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes","A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes","ONWARDS 11","Inclusion Criteria:\n\n* Diagnosed with type 1 diabetes mellitus greater than or equal to (≥) 1 year before screening.\n* Treated with multiple daily insulin injections (daily basal insulin analogue and bolus insulin analogue regimen) ≥ 6 months before screening.\n* HbA1c from 7.0-10.0 percentage (%) (53.0-85.8 millimoles per mole (mmol\u002Fmol)), both inclusive, at screening confirmed by central laboratory analysis.\n* Ability and willingness to adhere to the protocol including performance of self-measured plasma glucose (SMPG) profiles, based on the investigator's judgement.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to study intervention(s) or related products.\n* Previous participation in this study. Participation is defined as signed informed consent.\n* Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.\n* Exposure to an investigational medicinal product within 90 days or 5 half-lives of the investigational medicinal product (if known), whichever is longer, before screening.\n* Any condition, except for conditions associated with type 1 diabetes mellitus, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.\n* Anticipated initiation or anticipated change in concomitant medications (for more than 15 consecutive days) known to affect weight or glucose metabolism (e.g., treatment with thyroid hormones, or systemic corticosteroids).\n* Known hypoglycaemic unawareness as indicated by the Investigator according to Clarke's questionnaire question.\n* Recurrent severe hypoglycaemic episodes within the last year as judged by the investigator.",{"count":197,"type":22},877,[25],"This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.",[118],{"date":120,"type":35},{"date":203,"type":35},"2025-08-11",{"date":205,"type":22},"2027-03-01",{"name":41,"class":42},196,{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":23,"phases":218,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":229},"100491907","phase-3-a-research-study-looking-at-long-term-treatment-with-mim8-in-people-with-haemophilia-a-100491907","NCT05685238","A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A","Open-label, Long-term Safety and Efficacy Study of Mim8 in Participants With Haemophilia A With or Without Inhibitors","FRONTIER4","Arm 1 \\& 2:\n\nInclusion Criteria:\n\n1. Informed consent obtained before any study related activities. Study related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.\n2. Male or female with diagnosis of congenital haemophilia A based on medical records.\n3. Ongoing participation in study NN7769-4513, NN7769-4514, NN7769-4516, or NN7769-4728 at the time of transfer. Participant should qualify either of the following criteria:\n\n   1. Participant from study NN7769-4513, who has participated in the extension part of the study for at least 12 weeks prior to enrolment in study NN7769-4532, or,\n   2. Participant has completed the end of treatment visit for study NN7769-4514, NN7769-4516 or NN7769-4728.\n4. Participant and\u002For participant's parent(s)\u002Fparticipant's Legally acceptable representative (LAR) willingness and ability to comply with scheduled visits and study procedures, including the completion of diary.\n\nExclusion Criteria:\n\n1. Any disorder, except for conditions associated with haemophilia A, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.\n2. Participant who has discontinued or been withdrawn from studies NN7769-4513, NN7769-4514, NN7769-4516, or NN7769-4728.\n3. Previous participation in this study. Participation is defined as signed informed consent.\n4. Female who is pregnant, breast-feeding or intends to become pregnant.\n5. Female of child-bearing potential and not using a highly effective contraceptive method (highly effective contraceptive measures or as required by local regulation or practice).\n6. Participation (i.e., signed informed consent) in any interventional, clinical study (except from study NN7769-4513, NN7769-4514, NN7769-4516, or NN7769-4728) of an approved or non-approved investigational medicinal product.\n7. Any planned major surgery, during part 1 of the study.\n8. Mental incapacity, unwillingness to cooperate, or a language barrier precluding adequate understanding and cooperation.\n\nArm 3:\n\nInclusion criteria\n\n1. Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.\n2. Male or female with diagnosis of congenital severe haemophilia A (endogenous FVIII activity less than (\\\u003C) 1 percentage \\[%\\]) with or without FVIII inhibitors based on medical records.\n3. Aged \\\u003C1 year at the time of signing informed consent.\n4. Body weight greater than or equal to (≥) 3.2 kilograms at the time of signing informed consent.\n5. previously untreated patients (PUPs) or minimally treated patients (MTPs) (i.e., up to 5 days of exposure to haemophilia-related treatment such as plasma-derived FVIII, recombinant FVIII, fresh frozen plasma, cryoprecipitate, or whole blood products).\n6. Full-term pregnancy (gestational age ≥37 weeks).\n7. Participant's parent(s)\u002FLAR(s) willingness and ability to comply with scheduled visits and Arm 3 (infant) procedures, including the completion of diary and patient reported outcome (PRO) questionnaire.\n8. Participants \\\u003C3 months of age must show no signs of active intracranial haemorrhage at screening. This is confirmed by cranial ultrasound performed according to local practice and regardless of delivery method.\n9. Receipt of vitamin K prophylaxis (as per local standard practice).\n10. Availability of historical results in medical records for:\n\n    1. activated partial thromboplastin time (aPTT)\n    2. FVIII levels.\n11. Availability of historical results in medical records or pre-dose sample taken for:\n\n    1. fibrinogen\n    2. haematology parameters\n    3. biochemistry parameters (aspartate aminotransferase (AST) and\u002For alanine aminotransferase (ALT), bilirubin and creatinine).\n\nExclusion criteria\n\n1. Known or suspected hypersensitivity to trial product or related products.\n2. Previous participation in study 4532. Participation is defined as signed informed consent.\n3. Participation (i.e., signed informed consent) in any interventional clinical study with receipt of the last dose within 6 months (or 5 half-lives of the investigational medicinal product, whichever is shorter) before planned enrolment.\n4. Exposure to non-factor haemostatic products for bleeding prophylaxis within 6 months (or 5 half-lives of the medicinal product, whichever is shorter) before planned enrolment.\n5. Known congenital or acquired coagulation disorders other than haemophilia A.\n6. Other conditions (e.g., autoimmune disease) or laboratory abnormality that may increase the risk of bleeding or thrombosis, as evaluated by the investigator. Any disorder, except for conditions associated with haemophilia A, that in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol.\n7. Lack of adequate parental\u002Flegally acceptable representative (LAR) support to enter accurately and timely information regarding treatment and bleeding episodes into an (electronic) diary.\n8. Previous or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing) or signs of thromboembolic disease.\n9. Any planned major surgery, during part 1 of Arm 3 (infant). For definition of major surgery.\n10. Immune tolerance induction planned to take place after treatment initiation.\n11. Hepatic dysfunction defined as AST and\u002For ALT greater than (\\>) 3 times the upper limit of normal (ULN) combined with total bilirubin \\>1.5 times the ULN.\n12. Serum creatinine above 1.5 times the ULN.",{"count":217,"type":22},451,[25],"This study is looking at how Mim8 works in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used to avoid bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). The study will last for up to 5.5 years. The duration of the study depends on when the participant enrolled in this study. The study will end if Mim8 is approved and marketed in participant's country during the study, or the study will end in June 2028, whichever comes first. Participants will get up to 262 injections; the number of injections depends on how often participants will get injections and how long time participants take part in the study. While taking part in this study, there are some restrictions about what medicine participants can use. The study doctor will tell the participants more about this. In case the participants experience bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor. Female participants cannot take part if they are pregnant, breast-feeding or plan to get pregnant during the study period.",[221,222],"Haemophilia A","Haemophilia A With Inhibitors",{"date":100,"type":35},{"date":225,"type":35},"2023-02-13",{"date":227,"type":22},"2028-06-30",{"name":41,"class":42},152,{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":23,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":251},"100608919","phase-3-cleopattra-a-research-study-to-look-at-the-effects-of-treatment-with-a-medicine-called-coramitug-nnc6019-0001-in-people-with-heart-failure-due-to-transthyretin-amyloid-attr-amyloidosis-100608919","NCT07207811","CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis","CLEOPATTRA: Effects of NNC6019-0001 Versus Placebo on Cardiovascular Outcomes in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)","CLEOPATTRA","Inclusion Criteria:\n\n* Male or female.\n* Age 18 years or above at the time of signing the informed consent.\n* Have an established diagnosis of ATTR-CM (wild-type ATTR \\[ATTRwt\\] or variant ATTR \\[ATTRv\\]), with cardiac amyloid infiltration, increased left ventricular (LV) wall thickness, and HF.\n\nNote: Target ATTRv recruitment is approximately 15 percent of the study population.\n\na. Cardiac amyloid infiltration demonstrated by: i. Cardiac biopsy positive for TTR amyloid, OR ii. Grade 2 or 3 cardiac uptake at pyrophosphate (PYP)\u002Fdiphosphono-1,2-propanodicarboxylic acid (DPD)\u002F hydroxymethylene diphosphonate (HMDP) nuclear medicine imaging with single-photon emission computed tomography (SPECT) or SPECT\u002FCT (preferably) combined with an extracardiac biopsy positive for TTR amyloid, OR iii. Grade 2 or 3 cardiac uptake at PYP\u002FDPD\u002FHMDP nuclear medicine imaging with SPECT or SPECT\u002FCT (preferably) combined with normal serum free light chain ratio, and negative serum and urine protein electrophoresis with immunofixation (SPIE \\& UPIE)\u002For mass spectrometry based methods including mass fixation).\n\nNotes:\n\n* Non-invasive diagnostic pathway will be confirmed by a centralised expert review.\n* Bone tracer nuclear medicine imaging with SPECT or SPECT\u002FCT (preferably) will be conducted using 99m-technetium (Tc)-labelled pyrophosphate (99mTc-PYP), 99mTc-labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD), or 99mTc-labeled hydroxymethylene diphosphonate (99mTc-HMDP).\n* The eGFR adjusted acceptable serum free light chain ratio.\n* Patients with Grade 2 or 3 cardiac uptake at PYP\u002FDPD\u002FHDMP nuclear imaging with SPECT or SPECT\u002FCT (preferably) and evidence of monoclonal gammopathy of undetermined significance (MGUS; based on serum and urine protein electrophoresis and serum free light chains) will require endomyocardial biopsy with typing using mass spectrometry or immunohistochemistry to confirm presence of TTR protein in tissue.\n* Timing of serum free light chain ratio, SPIE, UPIE and mass spectrometry-based methods including mass fixation should be within 12 months of SPECT or SPECT\u002FCT nuclear imaging.\n\n  b. Increased LV wall thickness, as assessed by centralised review of echocardiography, showing interventricular septal wall thickness greater than or equal to 12 millimeter (mm).\n\n  c. Chronic HF (New York Heart Association \\[NYHA\\] Class I-IV): i. At least 1 documented hospitalisation for HF, OR ii. History of HF manifested by signs or symptoms of volume overload or elevated intracardiac pressures (e.g., elevated jugular venous pressure, shortness of breath, signs of pulmonary congestion on x-ray or auscultation, or peripheral oedema that required or requires ongoing treatment with a diuretic).\n  * Expected to be on stable cardiovascular medical therapy (defined as no greater than 50 percent dose adjustment and no categorical changes of medications), with the exception of diuretics, 4 weeks prior to the randomisation visit.\n  * Completed more than 50 meters on the 6MWT at screening.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to study intervention(s) or related products.\n* Current or previous participation (dosing with active treatment) in a study for an investigational ATTR depleting drug or ATTR gene editing therapy.\n* Total bilirubin greater than 3 times the upper limit of normal (ULN) at screening.\n* Current diagnosis or history of amyloid light chain, other non-ATTR amyloidosis, known leptomeningeal amyloidosis, or multiple myeloma.\n* HF not primarily caused by ATTR-CM (e.g., due to hypertension, valvular heart disease, or ischemic heart disease in the opinion of the investigator).\n* Currently hospitalised or hospitalised within 14 days prior to screening.\n* Currently treated with positive inotropic medication.\n* Uncorrected, severe, haemodynamically significant, left-sided heart valve disease.\n* Acute coronary syndrome, unstable angina, stroke, transient ischemic attack, coronary revascularisation, cardiac device implantation, cardiac valve repair, or major surgery within 60 days of screening.\n* Prior solid organ transplant or planned solid organ transplant during the study.\n* Left ventricular ejection fraction (LVEF) less than 30 percent as assessed by centralised review of echocardiography.\n* Presence or history of malignant neoplasm (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, carcinoma in situ\u002Fhigh-grade prostatic intraepithelial neoplasia \\[PIN\\], low-risk prostate cancer, or on stable therapy for prostate cancer) within 3 years before screening.\n* End-stage renal disease (estimated glomerular filtration rate \\[eGFR\\] less than 15 mL\u002Fmin\u002F1.73 m\\^2 at screening, or chronic\u002Fintermittent haemodialysis or peritoneal dialysis).",{"count":239,"type":22},1280,[25],"This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study will continue receiving their usual heart treatments as recommended by their doctor.",[243],"Transthyretin Amyloid Cardiomyopathy (ATTR CM)","2026-06-24",{"date":143,"type":35},{"date":247,"type":35},"2025-10-02",{"date":249,"type":22},"2029-06-29",{"name":41,"class":42},290,{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":23,"phases":262,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":83},"100637732","phase-1-a-research-study-to-compare-blood-levels-of-cagrilintide-after-multiple-doses-of-different-versions-of-cagrilintide-in-adults-with-overweight-or-obesity-100637732","NCT07597018","A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity","Bioequivalence Study of Cagrilintide B + Placebo Semaglutide I and Cagrilintide D Once Weekly in Participants With Overweight or Obesity","Inclusion Criteria:\n\n* Aged 18-64 years (both inclusive) at the time of signing informed consent\n* Body mass index (BMI) between 27.0 and 34.9 kilograms per square metre (kg\u002Fm\\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.\n* Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator.\n\nExclusion Criteria:\n\n* Previous participation in study(s) with an amylin analogue. Participation is defined as randomisation.\n* Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.","64 Years",{"count":261,"type":22},234,[138],"This clinical study is testing two versions of the study medicine cagrilintide. The purpose of the study is to compare these two versions to understand their effects in participants with overweight or obesity. Participants will receive either cagrilintide version D or cagrilintide version B, and which treatment participants receive is decided by chance. Participants will be in this clinical study for about 6 months.",[28,29],"2026-06-23",{"date":75,"type":35},{"date":268,"type":35},"2026-05-18",{"date":270,"type":22},"2027-06-01",{"name":41,"class":42},{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":23,"phases":281,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":291},"100640441","phase-1-evaluation-of-the-tolerability-of-cagrilintide-in-participants-not-tolerating-glp-1-ra-therapies-due-to-gastrointestinal-adverse-events-100640441","NCT07607587","Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events","Tolerability of Cagrilintide in People With Obesity That Discontinued GLP-1-RA Therapies Due to Gastrointestinal Adverse Events: a Double-blinded Randomised Feasibility Study","Key Inclusion Criteria:\n\n* Male or female (sex at birth)\n* Age 18 years or above at the time of signing the informed consent\n* History of documented treatment with GLP-1-RA medications with gastrointestinal (GI) adverse effects as the main reason for treatment discontinuation\n* Not suitable for re-initiation of GLP-1-RA treatment based on medical history and investigator judgement\n* Body mass index (BMI) greater than or equal to (≥) 30.0 kilograms per square meter (kg\u002Fm\\^2)\n\nKey Exclusion Criteria:\n\n* Female who is pregnant, breast-feeding, or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive methods\n* Treatment with GLP-1 receptor agonist or GLP-1-RA medication for any indication within 8 weeks before screening\n* History of type 1 or type 2 diabetes\n* Glycated haemoglobin (HbA1c) ≥ 6.5 percent (%) (48 millimole per mole \\[mmol\u002Fmol\\]) as measured by the central laboratory at screening\n* Treatment with glucose-lowering agent(s) prescribed for the indication of diabetes or pre-diabetes within 90 days before screening\n* Treatment with any medication prescribed for the indication of weight management within 8 weeks before screening",{"count":280,"type":22},114,[138],"The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participant will get is decided by chance. The study will last for about 8 months.",[28,29],"2026-06-22",{"date":143,"type":35},{"date":287,"type":35},"2026-05-29",{"date":289,"type":22},"2027-11-19",{"name":41,"class":42},11,{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":23,"phases":302,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":305,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":313},"100643909","phase-3-a-research-study-investigating-how-well-the-medicine-zenagamtide-helps-people-with-excess-body-weight-lose-weight-compared-to-semaglutide-100643909","NCT07668414","A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide","Efficacy and Safety of Zenagamtide s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Obesity (AMAZE 7)","AMAZE 7","Inclusion Criteria:\n\n* Male or female (sex at birth).\n* Age 18 years or above at the time of signing the informed consent.\n\nExclusion Criteria:\n\n* Glycated haemoglobin (HbA1c) ≥ 6.5% (48 millimoles per mole \\[mmol\u002Fmol\\]) as measured by the central laboratory at screening.\n* History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.\n* Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1\u002Fgastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues within 1 year before screening.",{"count":301,"type":22},650,[25],"The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.",[29,28],"NOT_YET_RECRUITING","2026-06-19",{"date":143,"type":35},{"date":309,"type":22},"2026-09-22",{"date":311,"type":22},"2028-10-10",{"name":41,"class":42},46,{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":91,"enrollmentInfo":321,"targetDuration":4,"studyType":23,"phases":322,"briefSummary":323,"conditions":324,"keywords":4,"overallStatus":305,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":325,"startDateStruct":326,"completionDateStruct":327,"leadSponsor":329,"locationsCount":330},"100643855","phase-2-a-research-study-comparing-how-well-different-doses-of-the-medicine-ubt251-lower-blood-sugar-in-people-with-type-2-diabetes-100643855","NCT07668388","A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes","Efficacy and Safety of Once-weekly Subcutaneous UBT251 in Participants With Type 2 Diabetes - a Dose-finding Study","Inclusion Criteria:\n\n* Male or female (sex assigned at birth, inclusive of all gender identities).\n* Age 18-75 years (both inclusive) at the time of signing the informed consent.\n* Diagnosed with type 2 diabetes greater than or equal to (≥) 180 days before screening.\n* Stable daily dose(s) ≥ 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator:\n\nmetformin with or without sodium-glucose cotransporter-2 (SGLT2) inhibitor.\n\n* HbA1c of 7.0-10.5 percent (%) (53-91 millimoles per mole (mmol\u002Fmol)) (both inclusive) as assessed by central laboratory at screening.\n* Body mass index between 25.0 kg\u002Fm\\^2 and 50.0 kg\u002Fm\\^2 (both inclusive) at screening.\n\nExclusion Criteria:\n\n* Treatment with any medication (prescription or over-the counter) or alternative remedies for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.\n* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.\n* Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire, question 8.",{"count":21,"type":22},[95],"The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes. Participants will either get UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Which treatment participants get is decided by chance. UBT251 is the treatment being tested and is not yet available for doctors to prescribe, while semaglutide is a medicine used to treat type 2 diabetes that doctors can already prescribe.",[98],{"date":143,"type":35},{"date":284,"type":22},{"date":328,"type":22},"2027-11-15",{"name":41,"class":42},69,{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":23,"phases":341,"briefSummary":342,"conditions":343,"keywords":4,"overallStatus":305,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":291},"100643877","phase-3-amaze-13-a-research-study-investigating-how-well-the-medicine-zenagamtide-helps-people-in-asia-with-excess-body-weight-lose-weight-100643877","NCT07668401","AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight","Efficacy and Safety of Zenagamtide s.c. Once-weekly in Asian Participants With Overweight or Obesity (AMAZE 13)","AMAZE 13","Inclusion Criteria:\n\n* Male or female (sex assigned at birth, inclusive of all gender identities).\n* Age 18 years or above at the time of signing the informed consent\n\nExclusion Criteria:\n\n* Glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol\u002Fmol) as measured by the central laboratory at screening.\n* History of type 1 or type 2 diabetes mellitus.\n* Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1\u002Fgastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening.",{"count":340,"type":22},400,[25],"The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide (the treatment being tested) or placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.",[28,29],{"date":143,"type":35},{"date":346,"type":22},"2027-01-07",{"date":348,"type":22},"2029-01-11",{"name":41,"class":42},{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":68,"sex":18,"minAge":19,"maxAge":259,"enrollmentInfo":357,"targetDuration":4,"studyType":23,"phases":359,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":362,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":83},"100636846","phase-1-a-research-study-to-evaluate-the-safety-of-nnc1679-0001-when-given-to-healthy-participants-and-participants-with-t2dm-100636846","NCT07570992","A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DM","A Phase 1,Double-blinded,Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of NNC1679-0001 When Administered to Healthy Participants and Participants With T2DM","Inclusion Criteria:\n\nAll participants\n\n* Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine eligibility for the study.\n* Male or female (sex at birth) of nonchildbearing potential.\n* Age 18-64 years (both inclusive) at the time of signing the informed consent.\n\nHealthy participants\n\n* Body mass index (BMI) 18.5-29.9 kilograms per square meter (kg\u002Fm\\^2) (both inclusive) at screening.\n* Glycated haemoglobin (HbA1c) lesser than or equal to (\\\u003C=) 6.4 percent (%) (47 \\[millimoles per mole\\] mmol\u002Fmol) at screening.\n* Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiograms (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator.\n\nParticipants with Type 2 Diabetes Mellitus (T2DM)\n\n* BMI 20.0-34.9 kg\u002Fm\\^2 (both inclusive) at screening.\n* HbA1c 6.5-9.0% (47.5-74.9 mmol\u002Fmol) at screening.\n* Diagnosed with T2DM greater than or equal to (\\>=)180 days before screening.\n* Stable (as judged by the investigator) daily dose(s) of metformin or combination of metformin and dipeptidyl peptidase IV (DPP-4) inhibitors and\u002For sodium-glucose co-transport 2 SGLT 2) inhibitors \\>= 90 days before screening.\n\nExclusion Criteria:\n\nAll participants\n\n* Screening alanine aminotransferase (ALT) values greater than (\\>) upper limit of normal (ULN) +10%, aspartate aminotransferase (AST) values \\>ULN +20%, or total bilirubin \\>ULN.\n* Renal impairment, defined as estimated glomerular filtration rate (eGFR) \\\u003C60.0 milliliter per minute per 1.73 square meter (mL\u002Fmin\u002F1.73m\\^2), at screening.\n* Clinical evidence of chronic kidney disease (CKD) and\u002For urinary albumin: creatinine ratio (UACR) \\>30 milligrams per gram (mg\u002Fg).\n* Presence or history of cardiovascular disease, including stable and unstable angina pectoris, myocardial infarction, transient ischaemic attack, stroke, cardiac decompensation, clinically significant arrhythmias, or clinically significant conduction disorders.\n\nHealthy participants\n\n* Any disorder that, in the investigator's opinion, might jeopardise participants' safety or compliance with the protocol.\n* Supine blood pressure at screening outside the range of 90-139 millimeters of mercury (mmHg) for systolic or 50-89 mmHg for diastolic.\n\nParticipants with T2DM\n\n* Any disorder except for mild conditions under stable treatment associated with T2DM, which in the investigator's opinion might jeopardise participant safety or compliance with the protocol.\n* Supine blood pressure at screening outside the range of 90-159 mmHg for systolic or 50-99 mmHg for diastolic. This exclusion criterion also pertains to those participants who are receiving antihypertensive treatment.",{"count":358,"type":22},58,[138],"This study is testing a new medicine that might help treat people with type 2 diabetes. The purpose of the study is to see if the new study medicine is safe and how well is tolerated by the body. There will be two groups of participants in this study: healthy participants and participants with type 2 diabetes. Participant will either get study medicine (NNC1679-0001) or placebo (a treatment that has no active medicine in it). NNC1679-0001 is a new experimental medicine that doctors cannot prescribe yet. Which treatment the participant gets is decided by chance. Participant will get one dose which will be injected into the area around abdomen (belly) by the medical staff.",[141,98],{"date":284,"type":35},{"date":364,"type":35},"2026-05-04",{"date":366,"type":22},"2028-06-25",{"name":41,"class":42},{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":374,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":18,"minAge":376,"maxAge":377,"enrollmentInfo":378,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":388},"100633913","a-real-world-study-to-investigate-cardiovascular-risk-profile-among-newly-diagnosed-type-2-diabetes-mellitus-t2dm-participants-100633913","NCT07532863","A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants","A Retrospective Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus Participants in Southeast Asia","CRISTALSEA","Inclusion Criteria:\n\n* Aged greater than equal to (≥) 40 and less than (\\\u003C) 70 years\n* Male or female\n* Newly diagnosed with T2DM and initiated on anti-hyperglycemic treatment between 1 January 2022 and 31 December 2023\n\nExclusion Criteria:\n\n* If any exclusion criterion is met, the participant will be excluded from the study.\n* T1DM or gestational diabetes\n* Prescribed with any anti-hyperglycemic medications before first diagnosis of T2DM\n* Pregnant women\n* With pre-existing atherosclerotic CVD including coronary heart disease, stroke, transient ischemic attack, or peripheral artery disease\n* Died within 12 months after first diagnosis of T2DM\n* Lost to follow-up i.e., no visit 12 months (± 3 months) after first diagnosis of T2DM","40 Years","70 Years",{"count":340,"type":22},"The purpose of the study is to investigate the cardiovascular disease (CVD) risk profile among participants newly diagnosed with type 2 diabetes mellitus (T2DM) in Southeast Asia (CRISTAL SEA). It's a retrospective chart-review across five Southeast Asian countries to characterize newly diagnosed T2DM participants and how their CVD risk is distributed, using data from the year before diagnosis and roughly the first year after diagnosis.",[98],{"date":382,"type":35},"2026-06-18",{"date":384,"type":35},"2026-03-13",{"date":386,"type":22},"2026-07-01",{"name":41,"class":42},6,{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":18,"minAge":397,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":23,"phases":400,"briefSummary":401,"conditions":402,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":411},"100563138","phase-3-a-study-to-evaluate-how-well-etavopivat-works-in-people-with-sickle-cell-disease-100563138","NCT06612268","A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease","A Global Phase 3, Randomised, Double-blind and Placebo-controlled Study Evaluating the Efficacy and Safety of Etavopivat in Adolescents and Adults With Sickle Cell Disease","Hibiscus 2","Inclusion Criteria:\n\n* Male or female.\n* Age 12 years or above at the time of signing the informed consent.\n* Confirmed diagnosis of sickle cell disease: Documentation of sickle cell disease (SCD) genotype (HbSS, HbSβ0-thalassemia or other sickle cell syndrome variants) based on prior history of laboratory testing or screening test results from central laboratory. Molecular genotyping is not required. SCD genotype may be determined from the results of haemoglobin (Hb) electrophoresis, high-performance liquid chromatography (HPLC) or similar testing. Note that Hb electrophoresis is performed by the central laboratory at screening.\n* Have 1-15 episodes of documented vaso occlusive crises (VOC) within the 12 months prior to screening. Documentation must exist in the participant's medical record prior to randomisation. Events based solely on participant recall without supporting documentation should not be counted towards eligibility.\n* Hb greater than or equal to (≥) 5.0 and less than or equal to (≤) 10.0 g\u002FdL (greater than or equal to (≥) 50 and less than or equal to (≤) 100 g\u002FL) at screening.\n\nExclusion Criteria:\n\n* More than 15 VOCs within the past 12 months prior to screening documented in the participant's medical record. Events based solely on participant recall without supporting documentation should not be counted towards eligibility.\n* Use of voxelotor or similar agent within 28 days prior to starting study treatment or anticipated need for this agent during the study.\n* Use of a selectin antagonist (e.g., crizanlizumab, monoclonal antibody or small molecule) within 28 days or 5 half-lives (whichever is longer) prior to starting study treatment or anticipated need for such agents during the study.\n* Receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion) or greater than or equal to 6 transfusion events in the previous 12 months (i.e., an average of 1 transfusion event every 60 days).\n* Participants who have received an RBC transfusion for any reason within 60 days of the screening period or 60 days of the randomisation day are only eligible if HbA (adult haemoglobin) less than 10% by Hb electrophoresis is documented prior to starting study treatment.\n* Receiving or use of concomitant medications that are strong inducers of CYP3A4 (cytochrome p450 3a4) within 2 weeks of starting study treatment or anticipated need for such agents during the study.\n* Use of erythropoietin or other haematopoietic growth factor treatment within 28 days of starting study treatment or anticipated need for such agents during the study.\n* Receipt of prior cellular-based therapy (e.g., haematopoietic cell transplant, gene modification therapy).\n* Hepatic dysfunction characterized by:\n\n  * Alanine aminotransferase (ALT) greater than 4.0 × upper limit of normal (ULN) or\n  * Direct bilirubin greater than 3.0 × ULN.\n* Participants who are not taking or are unable to take antimalarial prophylaxis at the time of consent and during the study if they live in areas of endemic malaria where prophylaxis is recommended.\n* Severe renal dysfunction (estimated glomerular filtration rate \\[eGFR\\] at screening, calculated by the central laboratory greater than 30 mL\u002Fmin\u002F1.73 m\\^ 2) or on chronic dialysis.\n* Travelled distance on standardized 6MWT below 100m at screening.","12 Years",{"count":399,"type":22},408,[25],"This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance. Etavopivat is a new medicine and is currently being tested in other studies in addition to this one. The study will last for about 2 years.",[403],"Sickle Cell Disease","2026-06-16",{"date":146,"type":35},{"date":407,"type":35},"2025-02-17",{"date":409,"type":22},"2029-03-12",{"name":41,"class":42},174,{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":23,"phases":420,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":83},"100610302","phase-1-examination-of-how-the-duration-of-fasting-and-temporary-stopping-of-glp-1-medications-affect-the-amount-of-food-left-in-the-stomach-in-people-using-liraglutide-injected-semaglutide-taken-by-mouth-or-semaglutide-injected-100610302","NCT07225816","Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)","Investigation of the Effect of Fasting Duration and Temporary Withholding of GLP-1 RAs on Retained Gastric Contents in Participants Treated With s.c. Liraglutide, Oral Semaglutide or s.c. Semaglutide","Inclusion Criteria:\n\n\\- On maintenance treatment with either liraglutide 3.0 milligram (mg) for at least 5 days, oral semaglutide 25 mg for at least 5 weeks or semaglutide 2.4 mg for at least 5 weeks prior to screening.\n\nExclusion Criteria:\n\n* Previous dosing in this study.\n* Previous rescreening for this study.\n* Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method\n* Current participation (i.e., signed informed consent) in any other interventional clinical study.\n* Exposure to investigational medicinal products, except maintenance treatment with liraglutide 3.0 mg, oral semaglutide 25 mg, or semaglutide 2.4 mg as required by the inclusion criterion, within 30 days or 5 half-lives of the investigational medicinal product (if known), which-ever is longer, before screening (Visit 1).\n* Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.\n* Anticipated change in lifestyle (e.g., eating, exercise or sleeping pattern) during the study.\n* Participant is the investigator or other site staff or relative thereof directly involved in the conduct of the study.\n* Mental incapacity, language barriers or unwillingness to comply with the requirements of the protocol, which may preclude adequate understanding or co-operation during the study as judged by the investigator.\n* Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator.\n* History of major surgical procedures involving the oesophagus or stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) or current presence of gastrointestinal implant a\\*.\n* Renal impairment with estimated glomerular filtration rate (eGFR) less than (\\\u003C) 30 milliliter per min per 1.73 square meter (ml\u002Fmin\u002F1.73 m\\^2) at screening based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation according to Kidney Disease Improving Global Outcomes (KDIGO) 20246.\n* Current treatment with insulin or secretagogues that might cause hypoglycaemia during periods of fasting.\n* History of ketoacidosis.\n* Diagnosed with or suspected to suffer from clinically significant gastroparesis, hiatal hernia or severe gastroesophageal reflux diseases with daily symptoms and\u002For in supine position.\n* Use of other medications known to affect the motility of the stomach.\n* Inability to lie in the right lateral decubitus position for gastric ultrasonography.\n* Unusual meal habits and special diet requirements or unwillingness to eat the meals provided in the study.\n\n  1. As declared by the participant or reported in the medical records.",{"count":5,"type":22},[138],"The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.",[28],"2026-06-15",{"date":404,"type":35},{"date":426,"type":35},"2025-11-07",{"date":428,"type":22},"2026-07-17",{"name":41,"class":42},{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":305,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":444,"completionDateStruct":445,"leadSponsor":447,"locationsCount":448},"100641221","research-study-to-examine-blood-sugar-control-treatment-satisfaction-and-adherence-in-people-with-type-2-diabetes-after-switching-from-daily-basal-insulin-to-once-weekly-insulin-icodec-100641221","NCT07658417","Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec","A Real-world, Multi-centre, Prospective, Non-interventional, Single-arm Study Investigating Glycaemic Control, Treatment Satisfaction and Adherence Associated With the Switch From Daily Basal Insulin to Insulin Icodec in People Living With Type 2 Diabetes in China","ICOSWITCH REAL","Inclusion Criteria:\n\n1. Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to protocol).\n2. The decision to initiate treatment with commercially available insulin icodec has been made by the participant\u002FLegally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include participant in this study.\n3. Male or female, age above or equal to 18 years at the time of signing informed consent.\n4. Diagnosed with T2D greater than or equal to (≥) 1 year before signing informed consent.\n5. Treated with once- or twice-daily basal insulin injections ≥ 6 months before signing informed consent. Any other antidiabetic medications are allowed, except for bolus insulin during the 90 days prior to switching to icodec for a period of 14 days or more.\n6. Available glycated haemoglobin (HbA1c) within 90 days prior to the 'Initiation visit' (V1) or HbA1c measurement taken in relation with the 'Initiation visit' (V1) if in line with local clinical practice.\n7. Treatment-naïve to once-weekly insulin prior to the 'Initiation Visit' (V1)\n\nExclusion Criteria:\n\n1. Previous participation in this study. Participation is defined as having given informed consent in this study.\n2. Treatment with any investigational drug within 30 days prior to enrolment into study.\n3. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.",{"count":439,"type":22},216,"The purpose of this study is to investigate the use of insulin icodec in the real-world setting in a population that broadly reflects people living with T2D and for whom switching to a once-weekly insulin icodec has been deemed relevant and beneficial by the treating physician. The study will last for approximately 30 weeks.",[98],"2026-06-13",{"date":284,"type":35},{"date":423,"type":22},{"date":446,"type":22},"2027-12-01",{"name":41,"class":42},15,{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":305,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":83},"100641810","patient-preferences-in-treatment-of-haemophilia-a-with-and-without-inhibitors-a-discrete-choice-experiment-in-germany-100641810","NCT07653139","Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany","Inclusion Criteria:\n\n* Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).\n* Participant has the mental capacity and sufficient German language proficiency to understand the study procedures and to complete the survey.\n* Age above or equal to 18 years at the time of signing informed consent.\n* Validated diagnose with haemophilia A, with and without inhibitors.\n* Resident in Germany.\n\nExclusion Criteria:\n\n* No provision of informed consent in this study.\n* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation\n* Age below 18 years at the time of signing informed consent.\n* Absence of a diagnosis of haemophilia A.\n* No residence in Germany.",{"count":456,"type":22},150,"This study aims to generate structured patient preference evidence on prophylactic treatment options for haemophilia A for adults with and without inhibitors to support health technology assessment and benefit evaluation processes. The study will examine how individuals with haemophilia A evaluate trade-offs between treatment effectiveness, safety, and treatment administration characteristics when choosing between prophylactic therapies. Participants will repeatedly choose between hypothetical treatment profiles that differ in clinically relevant attributes and levels.",[221],"2026-06-11",{"date":146,"type":35},{"date":462,"type":22},"2026-07-10",{"date":464,"type":22},"2026-10-26",{"name":41,"class":42},{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":4,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":473,"minAge":19,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":23,"phases":476,"briefSummary":478,"conditions":479,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":488},"100605046","phase-4-a-research-study-to-see-how-safe-is-eptacog-alfa-when-used-to-stop-heavy-bleeding-in-women-after-giving-birth-in-india-100605046","NCT07157423","A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India","Safety of Eptacog Alfa in Severe Postpartum Haemorrhage in India: A Phase IV Interventional Study","Inclusion Criteria:\n\n* Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study except for blood loss estimation post-partum\n* Adult women aged greater than or equal to (≥) 18 years at the time of signing the informed consent and who deliver after 27 weeks diagnosed with severe postpartum haemorrhage (PPH) who fail to respond to uterotonics\n\nExclusion Criteria:\n\n* Previous participation in this study. Participation is defined as having given informed consent in this study\n* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation\n* Patient with a history of thromboembolism\n* Patient with a history of bleeding disorders\n* Patient with a history of or ongoing disseminated intravascular coagulation (DIC); haemolysis, elevated liver enzymes, low platelet count (HELLP) syndrome, thrombotic thrombocytopenic purpura (TTP), pre-eclampsia or other severe complication of childbirth apart from severe PPH\n* Have undergone invasive obstetric procedures for the ongoing haemorrhage prior to trial enrolment (uterine balloon tamponade and external aortic compression not included)\n* Any chronic disorder or severe disease which, in the opinion of the Investigator, might jeopardise patient's safety or compliance with the protocol\n* Participation (i.e., signed informed consent) in any other interventional clinical study prior to screening in the current study","FEMALE",{"count":475,"type":22},64,[477],"PHASE4","This study will look at how safe is the medicine eptacog alfa when used in women in India for stopping heavy bleeding after giving birth. If participants have heavy bleeding after giving birth then they will get the medicine eptacog alfa. This study will be conducted to get more knowledge on the safety of the medicine eptacog alfa use in these women. At first participants will receive one dose of medicine eptacog alfa. If the given dose is not helpful to stop the bleeding, participants will get one additional dose. The study will last for about 30-35 days.",[480],"Severe Postpartum Haemorrhage",{"date":482,"type":35},"2026-06-12",{"date":484,"type":35},"2025-08-26",{"date":486,"type":22},"2027-03-26",{"name":41,"class":42},10,{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":496,"phases":4,"briefSummary":497,"conditions":498,"keywords":4,"overallStatus":500,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":501,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":502,"locationsCount":7},"100433271","compassionate-use-of-concizumab-if-you-have-haemophilia-100433271","NCT04921956","Compassionate Use of Concizumab if You Have Haemophilia","Concizumab Compassionate Use Programme for Patients With Congenital Haemophilia","Inclusion Criteria:\n\n* Informed consent obtained before any programme-related activities. Programme-related activities are any procedures that are carried out as part of the programme.\n* Patients with congenital haemophilia:\n\n  1. severe haemophilia A (coagulation factor VIII (FVIII) less than 1%) or moderate\u002Fsevere haemophilia B (coagulation factor IX (FIX) less than or equal to 2%) without inhibitors or\n  2. any haemophilia severity with documented history of inhibitors (more than or equal to 0.6 bethesda unit (BU)) who cannot be treated satisfactorily with authorised and marketed medicines (example: due to inhibitors or allergic reactions to factor-containing products, or due to poor venous access), and who are not able to enrol in clinical trials designed to support the development and registration of concizumab medicines (example: due to inhibitors or allergic reactions to factor-containing products, or due to poor venous access) as per investigator and Novo Nordisk assessment.\n* The potential benefit for the individual patient justifies the potential risks of treatment.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to investigational medicinal product or related products.\n* Any condition (current or medical history), which in the investigator's or Novo Nordisk's opinion might jeopardise patient's safety or compliance with the protocol.","EXPANDED_ACCESS","The compassionate use programme will give participants concizumab for free, even though it is not yet approved by health authorities. This is because participants need this medicine to treat their haemophilia properly. The programme will check that participants are safe and that the medicine works for them. The programme may last for years. Participants will take one injection under their skin every day. Participants will have 4-5 visits with the study doctor for the first half year. After that they will have 1 visit every half year. At all clinic visits participants will have blood samples taken. Participants will fill in a diary between the visits.\n\nA patient is considered to have completed the programme when any of the following criteria occurred first: 1) when the patient is included in a clinical trial with concizumab or 2) up to 6 months after concizumab is commercially available in the patient's country and approved for the patient (The time span of 6 months should provide ample time for the patient to obtain concizumab commercially) or 3) the sponsor decides to discontinue concizumab clinical development for the patient's population.",[499],"Congenital Haemophilia","AVAILABLE",{"date":423,"type":35},{"name":41,"class":42},""]